Provides that a retailer licensed by the office of cannabis management shall be permitted to sell any and all forms of cannabinoid hemp.
Summary
This bill would change New York’s cannabis law to expand the sale of cannabinoid hemp products by licensed retailers. Beginning January 1, 2026, retailers licensed by the Office of Cannabis Management would be permitted to sell any and all forms of cannabinoid hemp, so long as the products meet the requirements in the cannabis law. The bill also directs the Office of Cannabis Management to repeal certain emergency regulations and declares that any past or future rules that prohibit the sale of any form of cannabinoid hemp are null and void.
The bill revises key definitions in the cannabis law, including narrowing the definition of THC to Delta-9-tetrahydrocannabinol and changing the definition of “total THC” to focus on dry-weight Delta-9 content. It also changes the rules for cannabinoid hemp flower products intended for smoking, allowing them to be sold to adults age 21 and older rather than limiting them to adult-use cannabis dispensaries. In addition, it imposes specific labeling requirements for hemp-derived cannabinoid products, including a nutrition label with serving size, a warning that the product is not meant to treat or cure medical ailments and is not FDA-regulated, the amount of hemp-derived product per serving, and the manufacturer or distributor’s address.
Impact
The bill would significantly affect the regulation of hemp-derived cannabinoid products under the Cannabis Law by limiting the state’s ability to restrict their sale through emergency regulations or other rulemaking. It would expand retail access for cannabinoid hemp, alter statutory definitions used for THC and product compliance, and create mandatory labeling standards for hemp-derived cannabinoid products. It would also shift the market for smokable cannabinoid hemp flower by allowing sales to adults 21 and over in licensed retail settings, potentially broadening distribution beyond the current framework.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of legislative debate or formal support/opposition in the available record. Based on the bill text alone, the measure appears to be framed as a deregulatory and market-expanding proposal for hemp retailers, with a strong emphasis on limiting state restrictions while preserving safety and labeling requirements. The overall tone suggests support for broader commercial access to cannabinoid hemp products.
Contention
The main point of contention is likely the bill’s restriction on the Office of Cannabis Management and the Cannabis Control Board, which would be barred from using rules or emergency regulations to prohibit sales of any form of cannabinoid hemp. Opponents may view this as weakening regulatory oversight and public-health protections, especially for smokable hemp products and intoxicating cannabinoid products. Supporters are likely to argue that the bill provides clarity for retailers, preserves consumer access, and establishes baseline labeling and age restrictions rather than a blanket prohibition.